top of page

Autoimmune-Summaries: Daily Autoimmune Updates at a Glance

decodeMR Team
Sep 10
1 min read


09/09/2026










UCB received US FDA BTD for CIMZIA in pregnant women with antiphospholipid syndrome. (Ref)


UCB announced that the US FDA had granted Breakthrough Therapy Designation (BTD) to CIMZIA® (certolizumab pegol) for the prevention of placenta-mediated adverse pregnancy outcomes in addition to standard anti-coagulant therapy, in at-risk pregnant adult women who have antiphospholipid syndrome (APS) and are positive for lupus anticoagulant (LA).


  • The BTD was supported by findings from the investigator-initiated IMPACT study, which demonstrated the potential of CIMZIA® to address a significant unmet need for women with APS.














Beeline Medicines announced topline results from the Phase 2 study of afimetoran in SLE. (Ref)


Beeline Medicines announced positive topline results from the Phase 2/ NCT04895696 study of afimetoran (TLR7 and TLR8 inhibitor) in systemic lupus erythematosus (SLE).


  • The study met its primary endpoint, with with all three afimetoran dose groups demonstrating higher SRI-4 response rates vs placebo at Week 48 (p-value <0.001 across all dose groups).


  • Secondary endpoints demonstrated improvements consistent with the primary endpoint findings.


  • The safety and tolerability of afimetoran were generally consistent with previous Phase 1 clinical trial experience, and no new safety signals were observed.


  • Afimetoran previously demonstrated exploratory efficacy in a Phase 1b study in cutaneous lupus erythematosus and was granted Fast Track designation by the US FDA for SLE in May 2025.


  •  The Company planned to advance afimetoran into pivotal development for both SLE and CLE.


bottom of page